NO20072206L - Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens - Google Patents

Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens

Info

Publication number
NO20072206L
NO20072206L NO20072206A NO20072206A NO20072206L NO 20072206 L NO20072206 L NO 20072206L NO 20072206 A NO20072206 A NO 20072206A NO 20072206 A NO20072206 A NO 20072206A NO 20072206 L NO20072206 L NO 20072206L
Authority
NO
Norway
Prior art keywords
disease
alzheimer
amyloid
investigating
procedures
Prior art date
Application number
NO20072206A
Other languages
English (en)
Norwegian (no)
Inventor
Shigeo Takayama
Yuji Yamada
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO20072206L publication Critical patent/NO20072206L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G01N33/541—Double or second antibody, i.e. precipitating antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20072206A 2004-10-28 2007-04-30 Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens NO20072206L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004314639 2004-10-28
JP2005052003 2005-02-25
PCT/JP2005/019787 WO2006046644A1 (fr) 2004-10-28 2005-10-27 Procédé d’examen de la maladie d’alzheimer et réactif de diagnostic

Publications (1)

Publication Number Publication Date
NO20072206L true NO20072206L (no) 2007-07-30

Family

ID=36227886

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072206A NO20072206L (no) 2004-10-28 2007-04-30 Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens

Country Status (13)

Country Link
US (1) US20080199879A1 (fr)
EP (1) EP1813947A4 (fr)
JP (1) JPWO2006046644A1 (fr)
KR (1) KR20070073778A (fr)
CN (1) CN101048662A (fr)
AU (1) AU2005297854A1 (fr)
BR (1) BRPI0516674A (fr)
CA (1) CA2585148A1 (fr)
IL (1) IL182540A0 (fr)
MX (1) MX2007005053A (fr)
NO (1) NO20072206L (fr)
RU (1) RU2007119535A (fr)
WO (1) WO2006046644A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
EP2361638B1 (fr) 2005-12-12 2014-01-15 AC Immune S.A. Anticorps monoclonaux spécifiques de A beta 1-42 avec des propriétés thérapeutiques
WO2007119685A1 (fr) * 2006-04-13 2007-10-25 Sanko Junyaku Co., Ltd. MÉTHODE POUR DÉPISTER LA MALADIE D'ALZHEIMER PAR DOSAGE DU TAUX DE DÉGRADATION DE ß-AMYLOÏDE DANS LE SANG ET RÉACTIF DE DIAGNOSTIC
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
JP4683298B2 (ja) * 2006-08-21 2011-05-18 アイシン精機株式会社 被検物質の免疫測定方法、及び免疫結合親和性解析の制御方法
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
ES2533484T3 (es) 2007-04-18 2015-04-10 Probiodrug Ag Derivados de tiourea como inhibidores de la glutaminil ciclasa
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
WO2009016734A1 (fr) * 2007-07-31 2009-02-05 University Of Tsukuba Procédé pour la détection d'un trouble cognitif léger
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
CN101878301B (zh) * 2007-10-29 2014-08-20 道健康生活医药株式会社 抗体及其应用
US20110263450A1 (en) * 2008-09-26 2011-10-27 The University Of Melbourne Alzheimer's disease biomarkers
EA022007B1 (ru) 2009-09-11 2015-10-30 Пробиодруг Аг Гетероциклические производные в качестве ингибиторов глутаминилциклазы
BR112012014060B8 (pt) 2009-12-11 2021-07-27 Araclon Biotech Sl método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda
JP5400903B2 (ja) * 2010-01-28 2014-01-29 パナソニック株式会社 アミロイドβ測定方法
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
KR101790806B1 (ko) 2010-03-10 2017-11-20 프로비오드룩 아게 글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제
WO2011130377A2 (fr) 2010-04-15 2011-10-20 Abbott Laboratories Protéines de liaison à la bêta amyloïde
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
WO2012123563A1 (fr) 2011-03-16 2012-09-20 Probiodrug Ag Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
WO2012142300A2 (fr) * 2011-04-12 2012-10-18 Quanterix Corporation Procédé de détermination d'un protocole de traitement et/ou d'un pronostic de rétablissement d'un patient à la suite d'un traumatisme cérébral provenant d'un événement hypoxique
EP2511296A1 (fr) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Anticorps, kit et procédé pour déterminer des peptides amyloïdes
US9541561B2 (en) 2012-06-14 2017-01-10 Electronics And Telecommunications Research Institute Method for diagnosing Alzheimer's disease using biomaterial
JP5991666B2 (ja) * 2012-07-04 2016-09-14 公立大学法人大阪市立大学 アルツハイマー病を検出する方法及びキット
JP2016103980A (ja) * 2013-03-08 2016-06-09 パナソニックヘルスケア株式会社 ハイブリドーマ及びモノクローナル抗体
US20200166507A1 (en) * 2016-02-15 2020-05-28 Nobelpharma Co., Ltd. Measurement method and measurement kit for proteins related to genetic diseases
EP3242134A1 (fr) * 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Dosage pour le diagnostic d'une maladie neurologique
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN113311153B (zh) * 2021-05-12 2023-05-26 华中科技大学 一种用于阿尔茨海默病诊疗一体化的多功能的纳米粒子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411974A1 (fr) * 1989-07-05 1991-02-06 N.V. Innogenetics S.A. Anticorps monoclonaux contre une antigène d'enchevêtrements neurofibrillaires
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
DE50103881D1 (de) * 2001-06-12 2004-11-04 Wiltfang Jens Monoklonaler Antikörper, mbAb 1E8, welcher für die zwei ersten N-terminalen Aminosäuren von Amyloid-beta-Peptiden spezifisch ist und dessen Verwendung zum Nachweis von Amyloid-beta Peptiden und/oder sAPPa
CA2457502A1 (fr) * 2001-08-10 2003-03-06 Ming-Chih Crouthamel Gamma-3 protease
CA2477675C (fr) * 2002-03-05 2013-05-21 Ramot At Tel-Aviv University Ltd. Composition immunisante et procede permettant d'induire une reponse immunitaire contre le site de clivage de .beta.-secretase de la proteine du precurseur de l'amyloide

Also Published As

Publication number Publication date
IL182540A0 (en) 2007-09-20
MX2007005053A (es) 2007-06-19
CA2585148A1 (fr) 2006-05-04
US20080199879A1 (en) 2008-08-21
EP1813947A4 (fr) 2008-06-11
JPWO2006046644A1 (ja) 2008-05-22
RU2007119535A (ru) 2008-12-10
KR20070073778A (ko) 2007-07-10
BRPI0516674A (pt) 2008-09-16
AU2005297854A1 (en) 2006-05-04
EP1813947A1 (fr) 2007-08-01
WO2006046644A1 (fr) 2006-05-04
CN101048662A (zh) 2007-10-03

Similar Documents

Publication Publication Date Title
NO20072206L (no) Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens
Lleo et al. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
CN106574930B (zh) 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法
Zetterberg et al. Fluid markers of traumatic brain injury
US9709573B2 (en) Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
ATE535535T1 (de) Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
Dedong et al. Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients
BRPI0619748A8 (pt) anticorpo monoclonal, polinucleotídeo, região variável de cadeia leve, região variável de cadeia pesada, composição, mistura, métodos para produzir um anticorpo, para preparar uma composição farmacêutica ou uma mistura, de diagnóstico de uma doença ou condição associada a amilóide, para determinar o grau de carga de placa amiloidogênica em um tecido, para diagnosticar uma predisposição para uma doença ou condição, para monitorar doença residual mínima e para prever responsabilidade de um paciente, uso de um anticorpo monoclonal e/ou uma parte funcional do mesmo e/ou uma composição farmacêutica ou uma mistura, linhagem celular de hibridoma, e, kits de teste
DK3171174T3 (en) Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease
WO2009152607A8 (fr) Procédés et kits pour diagnostiquer une maladie neurodégénérative
EP1977234A4 (fr) Molecules permettant le traitement d'une maladie pulmonaire mettant en jeu une reaction immunitaire a un tissu conjonctif trouve dans le poumon
WO2006107962A3 (fr) Procedes et produits pour evaluer une reponse immunitaire a un agent therapeutique
TW201033616A (en) Urine and serum biomarkers associated with diabetic nephropathy
Stewart et al. Cheek cell–derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control
JP2010537200A (ja) 改善されたアルツハイマー診断法
Pérez-Grijalba et al. Validation of immunoassay-based tools for the comprehensive quantification of Aβ 40 and Aβ 42 peptides in plasma
Shea et al. Amyloid-β oligomers: multiple moving targets
WO2011066583A1 (fr) Agrégats de bêta-amyloïdes présents dans le liquide céphalorachidien utilisés comme biomarqueurs pour la maladie d'alzheimer
CN110168374A (zh) 用于对阿尔茨海默病的鉴别诊断的组合测试
TW201542821A (zh) 牙周病原菌血漿或血清抗體價檢查套組
Post et al. Toward a reliable distinction between patients with mild cognitive impairment and Alzheimer-type dementia versus major depression
CN111630382A (zh) α-共核蛋白病的测定、方法和治疗
BR112022000322A2 (pt) Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer
CN109073661A (zh) 用于神经学疾病的诊断的测定法
ATE437182T1 (de) Diagnose von allergischen erkrankungen, atopischen erkrankungen und/oder autoimmunerkrankungen durch nachweis von autoantikörpern gegen cd28 in humanem serum